Hospitals

We’ve improved personalized cell therapy manufacturing at hospitals, known as point-of-care (POC), to ensure security, reliability, and scalability.

• Immutable end-to-end audit trails to comply with standards and regulations to ensure transparency, trust and quality

• Supply Chain orchestration and optimization helping to improve processing costs increasing ROI in personalized treatments
• Process Automation: We’ve automated processes and introduced enterprise-grade capabilities. Clinicians can now adjust manufacturing in real-time based on patient responses
• Highest industry standards: end to end pharma validated, FDA 21 CRF Part 11 compliant, GxP grade solution, ISBT-128 compliant labeling
• Secure and private by default – transparent where needed 
• Flexible and adoptable: level of product lifecycle (pre-clinical to commercialization) AND type of ATMP (allogenic, autologous, …) can be adjusted to cover future needs

We support point-of-care manufacturing, providing faster access to therapies and promoting innovation in hospital-based cell therapy development.

Our innovations aim to make personalized therapies more accessible, secure, and efficient while fostering innovation in hospital-based cell therapy manufacturing.